|
See/download the final announcement!
Short Oral Communications
Day-at-a-glance:
Saturday Sunday
Monday Tuesday
Wednesday
Outline programme
[PDF]
Abstracts
available here
Invited
speaker abstracts
Short Orals
1 (CLINICAL) Short Orals 2 (BASIC) Short
Orals 3 (CLINICAL) Short Orals 4
(BASIC) |
| |
| Sunday 25 May, 2008 |
16:30-
17:30 |
 |
Short
Oral Communications 1: Clinical
Chairs: Carlos Gómez Alonso (Oviedo, Spain)
Bente Langdahl (Aarhus, Denmark) |
|
| 16:30 |
Su-OP01 |
A SET OF GENES EXPRESSED IN BREAST CANCER BONE METASTASES
DISCLOSES PREDISPOSITION TO GENERATE METASTASES IN MULTIPLE ORGANS
M. Capulli*1, A. Angelucci2, N. Rucci1,
F. Martella3, M. Bologna2, L. Ventura4,
O. Moreschini5, S. Pelle5, K. Driouch6,
T. Landemaine6, R. Lidereau6, P. Clement-Lacroix7,
T. Garcia7, A. Teti1, E. Ricevuto3
1Department of Experimental Medicine, 2Department
of Basic Applied Biology, 3U.O. Medical Oncology, University
of L'Aquila, 4Department of Pathology, San Salvatore Hospital,
L'Aquila, 5Orthopoedic and traumatology Department, University
of Rome "La Sapienza", Rome, Italy, 6Oncogenetic
Laboratory, Centre René Huguenin, Institut de la Santé
et de la Recherche Médicale, St.Cloud, 7Proskelia,a
Galapagos Company, PROSTRAKAN, Romainville, France |
|
| 16:35 |
Su-OP02 |
NOVEL ASSOCIATION BETWEEN A POLYMORPHISM IN THE P2X7
RECEPTOR GENE AND LOSS OF LUMBAR SPINE BONE MINERAL DENSITY IN POSTMENOPAUSAL
WOMEN
A. Gartland*1, K. K. Skarrat2, L. J. Hocking3,
R. Clifton-Bligh2, C. Parsons3, W. D. Fraser4,
D. M. Reid3, J. A. Gallagher5, J. S. Wiley2
1School of Medicine and Biomedical Sciences, The University
of Sheffield, Sheffield, United Kingdom, 2Department of
Medicine, University of Sydney at Nepean Hospital, Penrith, Australia,
3Department of Medicine and Therapeutics, University of
Aberdeen, Aberdeen, 4 School of Clinical Science, 5School
of Biomedical Sciences, The University of Liverpool, Liverpool, United
Kingdom |
|
| 16:40 |
Su-OP03 |
EFFECTS OF COL1A1 POLYMORPHISMS AND HAPLOTYPES ON PERIMENOPAUSAL
BONE MASS AND POSTMENOPAUSAL BONE LOSS
N. Gonzalez-Bofill*1, L. B. Husted1, P. Vestergaard1,
C. L. Tofteng2, B. Abrahamsen3, P. Eiken4,
B. L. Langdahl1
1Endocrinology, Århus
University Hospital, Århus, 2Endocrinology, Copenhagen
University Hospital, Hvidovre, 3Endocrinology, Copenhagen
University Hospital, Gentofte, 4Endocrinology, Hillerød
Hospital, Hillerød, Denmark |
|
| 16:45 |
Su-OP04 |
FUNCTIONAL ROLE OF TNFSF11 GENE PROMOTER POLYMORPHISMS
IN POSTMENOPAUSAL OSTEOPOROSIS
S. Mencej*1, O. M. E. Albagha2, J. Prezelj3,
T. Kocjan3, J. Marc1
1Chair of
Clinical Biochemistry, University of Ljubljana, Faculty of Pharmacy,
Ljubljana, Slovenia, 2Rheumatic Diseases Unit, University
of Edinburgh, Western General Hospital, Edinburgh, United Kingdom,
3Department of Endocrinology, Diabetes and Metabolic Diseases,
University Medical Centre, Ljubljana, Slovenia |
|
| 16:50 |
Su-OP05 |
PROMOTER AND INTRON 1 POLYMORPHISMS OF
COLIA1 PREDISPOSE TO OSTEOPOROSIS BY REGULATING TRANSCRIPTION AND
ALTERING BINDING OF SP1, NMP4 AND OSTERIX
H. Jin*1, O. M. E. Albagha1, R. J. Van't Hof1,
S. H. Ralston1
1Molecular Medicine Centre,
University of Edinburgh, Edinburgh, United Kingdom |
|
| 16:55 |
Su-OP06 |
BOTH N- AND C-TERMINAL FRAGMENTS OF PARATHYROID
HORMONE-RELATED PROTEIN (PTHRP) REVERSE THE CATABOLIC EFFECTS OF 3-METHYLPREDNISOLONE
ON BONE REGENERATION IN MICE.
L. F de Castro*1, D. Lozano1, E. Gómez-Barrena2,
F. Manzarbeitia3, P. Esbrit1
1Bone
and Mineral Metabolism Laboratory, 2Traumatologic Department,
3Pathology Department, Fundación Jimenez Díaz,
Madrid, Spain |
|
| 17:00 |
Su-OP07 |
EFFECT OF VITAMIN-D3 AND CALCIUM ON FRACTURE
RISK IN 65-71 YEAR OLD WOMEN IN A 3-YEAR RANDOMIZED CLINICAL TRIAL
– PRELIMINARY RESULTS OF THE OSTPRE-FRACTURE PREVENTION STUDY
K. T. J. Salovaara*1, M. Tuppurainen2, T. Rikkonen1,
M. Karkkainen1, J. Sirola1, R. Honkanen1,
E. Alhava3, H. Kroger4
1Bone
and Cartilage Research Unit, University of Kuopio, 2Department
of Gynecology and Obstetrics, University Hospital of Kuopio, 3Department
of Surgery, University of Kuopio, 4Department of Orthopedics,
Traumatology and Hand Surgery, University Hospital of Kuopio, KUOPIO,
Finland |
|
| 17:05 |
Su-OP08 |
NON-OSTEOPOROTIC WEDGE DEFORMITY AND OSTEOPOROTIC
VERTEBRAL FRACTURE IMAGED BY X-RAY ABSORPTIOMETRY IN PRE- AND POSTMENOPAUSAL
WOMEN (OPUS STUDY)
L. Ferrar*1, G. Jiang1, D. M. Reid2,
C. Roux3, D. Felsenberg4, C. Glueer5,
R. Eastell1
1School of Medicine and Biomedical
Science, University of Sheffield, Sheffield, 2Dept of Medicine
and Therapeutics, University of Aberdeen, Aberdeen, United Kingdom,
3Centre d'Evaluation des Malades Osseuses, Rene Descartes
University, Paris, France, 4Centre of Bone and Muscle Research,
Universitatsmedizin Berlin, Berlin, 5Diagnostic Radiology,
University Hospital Schleswig-Hostein, Kiel, Germany |
|
| 17:10 |
Su-OP09 |
EFFECT OF THYROID STATUS ON THE SKELETON
IN POST-MENOPAUSAL WOMEN: THE OPUS STUDY
E. Murphy*1, C. Glueer2, D. M. Reid3,
D. Felsenberg4, C. Roux5, R. Eastell6,
G. R. Williams1
1Molecular Endocrinology,
Imperial College London, London, United Kingdom, 2Arbeitsgruppe
Medizinische Physik, Universitatsklinikum Schleswig-Holstein, Kiel,
Germany, 3Medicine & Therapeutics, University of Aberdeen,
Aberdeen, United Kingdom, 4Zentrum Muskel & Knochenforshung,
Freie & Humboldt Universitat Berlin, Berlin, Germany, 5Centre
d'Evaluation des Maladies Osseuses, Hopital Cochin, Paris, France,
6Academic Unit of Bone Metabolism, Northern General Hospital,
Sheffield, United Kingdom |
|
| 17:15 |
Su-OP10 |
INFLUENCE OF MENARCHEAL AGE ON DISTAL
TIBIA MICROSTRUCTURE IN 20-YEAR OLD AND PREMENOPAUSAL MIDDLE-AGED
WOMEN
T. Chevalley*1, J. Bonjour1, S. Ferrari1,
R. Rizzoli1
1Service of Bone Diseases, Department
of Rehabilitation and Geriatrics, University Hospitals and Faculty
of Medicine, Geneva, Switzerland |
|
16:30-
17:30 |
|
Short
Oral Communications 2: Basic
Chairs: Gabriel Herrero Boumont (Madrid, Spain)
Hans van Leeuwen (Rotterdam, Netherlands) |
|
| 16:30 |
Su-OP11 |
ACTIVATION OF THE CANONICAL WNT SIGNALING PATHWAY INDUCES
CHONDROCYTE DEDIFFERENTIATION
R. L. Miclea*1, E. C. Robanus-Maandag2, H. Bloys3,
C. W. G. M. Löwik3, J. M. Wit1, M. Karperien4
1Pediatrics, 2Human Genetics, 3Endocrinology,
Leiden University Medical Centre, Leiden, 4Institute for
Biomedical Technology, University of Twente, Enschede, Netherlands
|
|
| 16:35 |
Su-OP12 |
MYOSTATIN DEFICIENCY INCREASES CORTICAL BONE FORMATION
INDEPENDENT OF CHANGES IN GROUND REACTION FORCES DURING NORMAL LOCOMOTION
M. W. Hamrick*1, S. Ponnala1, A. Zumwalt2,
D. Schmitt3
1Cellular Biology and Anatomy,
Medical College of Georgia, Augusta, 2Anatomy, Boston University,
Boston, 3Biological Anthropology and Anatomy, Duke University,
Durham, United States |
|
| 16:40 |
Su-OP13 |
IN VITRO OSTEOCLASTOGENESIS AND BONE RESORPTION DURING
SPACEFLIGHT
R. Tamma1, G. Colaianni1, C. Camerino1,
A. Di Benedetto*1, G. Greco1, M. Strippoli1,
R. Vergari1, A. Grano1, L. Mancini1,
A. Zallone1
1Human Anatomy and Histology,
University of Bari, Bari, Italy |
|
| 16:45 |
Su-OP14 |
MYELOMA CELL-INDUCED COLLAPSE OF THE VASCULAR BONE
REMODELING COMPARTMENTS LEADS TO OSTEOLYSIS AND THE GENERATION OF
OSTEOCLAST-MYELOMA HYBRID CELLS
T. L. Andersen*1, K. Søe1, T. E. Sondergaard1,
K. Kupisiewicz1, T. Plesner2, J. M. Delaisse1
1Department of Clinical Cell Biology, 2Department
of Hematology, Vejle Hospital, IRS-CSFU, Sourthern Denmark University,
Vejle, Denmark |
|
| 16:50 |
Su-OP15 |
CANCER STRESS AFFECTS TRANSCRIPTOME OF
BONE CELLS: METASTASES AND MULTIPLE MYELOMA GENERATE DISTINCT TRANSCRIPTIONAL
FOOTPRINTS IN OSTEOCYTES IN VIVO
K. Ackermann*1, S. Eisenberger1, W. Pyerin1
1Biochemical Cell Physiology A135, German Cancer Research
Center, Heidelberg, Germany |
|
| 16:55 |
Su-OP16 |
IN VIVO AND IN VITRO BONE PHENOTYPE CHARACTERIZATION
OF THE IMMUNODEFICIENT ADA-KO MOUSE
A. V. Sauer*1, E. Mrak2, E. Zacchi2,
R. Jofra Hernandez1, A. Tabucchi3, A. Rubinacci2,
A. Aiuti1
1hsr-TIGET, 2Bone Metabolic
Unit, San Raffaele Hospital, Milan, 3Institute of Biochemistry
and Enzymology, University of Siena, Siena, Italy |
|
| 17:00 |
Su-OP17 |
THE IKK INHIBITORS CELASTROL AND PARTHENOLIDE
INHIBIT BREAST CANCER CELL PROLIFERATION AND MIGRATION IN VITRO AND
OSTEOLYTIC BONE METASTASIS IN VIVO
A. I. Idris*1, H. Libouban2, H. Nyangoga2,
E. Landao-Bassonga1, D. Chappard2, S. H. Ralston1
1Rheumatology, University of Edinburgh, Edinburgh, United
Kingdom, 2Faculté de Médecine, INSERM, Angers,
France |
|
| 17:05 |
Su-OP18 |
TNF-RELATED APOPTOSIS INDUCING LIGAND
(TRAIL) INHIBITS PRIMARY BONE TUMOR GROWTH AND AUGMENTS SURVIVAL IN
A HUMAN MODEL EWING SARCOMA
L. Geffroy1, D. Chauviere1, F. Lamoureux1,
G. Picarda1, O. Delattre2, S. Burchill3,
P. Delepine4, F. Gouin1, D. Heymann5,
F. Redini*1
1EA 3822 - INSERM ERI 7, Faculté
de Médecine, Nantes cedex 1, 2INSERM U830, Institut
Curie, Paris, France, 3Leeds Institute of Molecular Medicine,
St James Univ Hosp, Leeds, United Kingdom, 4INSERM U613,
Université de Bretagne occidentale, Brest, 5EA 3822
- INSERM ERI 7, Faculté de Médecine, Nantes, France
|
|
| 17:10 |
Su-OP19 |
SKELETON REGULATES PANCREATIC FUNCTION
VIA BONE MORPHOGENETIC PROTEIN-6 (BMP-6)
P. Simic*1, L. Grgurevic1, I. Orlic1,
A. Tikvica1, M. Zuvic2, S. Vukicevic1
1Laboratory for Mineralized Tissues, Department of Anatomy,
2Department of Nuclear Medicie, School of Medicine University
of Zagreb, Zagreb, Croatia |
|
| 17:15 |
Su-OP20 |
SILENCING LAMIN A/C DECREASES OSTEOBLAST
DIFFERENTIATION AND STIMULATES OSTEOCLASTOGENESIS THROUGH ENHANCED
RANKL SIGNALING
M. Rauner*1, W. Sipos2, R. Foisner3,
L. Hofbauer4, P. Pietschmann1
1Institute
of Pathophysiology, Medical University of Vienna, 2II Medical
Clinic, University of Veterinary Medicine, 3Max F. Perutz
Laboratories, Medical University of Vienna, Vienna, Austria, 4Division
of Endocrinology and Bone Diseases, Medical Faculty, Technical University
of Dresden, Dresden, Germany |
|
| Monday 26 May, 2008 |
|
16:30-
17:30 |
|
Short
Oral Communications 3: Clinical
Chairs: Nuria Guañabens (Barcelona, Spain)
Graham Russell (Oxford, UK) |
|
| 16:30 |
Mo-OP21 |
SERUM HOMOCYSTEINE LEVELS AND BONE MATRIX QUALITY
S. Blouin*1, H. W. Thaler2, E. Paschalis1,
J. Hofstaetter1, C. Korninger3, R. Schmid4,
P. Roschger1, K. Klaushofer1
1Ludwig
Boltzman Institute of Osteology, Hanusch Hospital of WGKK, AUVA Trauma
Centre Meidling and 4th Medical Department, Hanusch Hospital, 2,
AUVA Trauma Centre Meidling, 3, AUVA Trauma Centre Lorenz
Boehler Hospital, 4Department of Medical & Chemical
Labdiagnostics, Vienna General Hospital, Vienna, Austria |
|
| 16:35 |
Mo-OP22 |
COLLAGEN’S CONTRIBUTION TO BONE STRENGTH
E. P. Paschalis*1, P. Roschger1, P. Fratzl2,
R. Zoehrer1, A. Roschger1, I. Manjubala2,
S. Gamsjaeger1, P. Zysset3, S. P. Robins4,
K. Klaushofer1
14th Medical Department,
Ludwig Boltzmann Institute for Osteology, Vienna, Austria, 2Department
of Biomaterials, Max Planck Institute of Colloids and Interfaces,
Potsdam, Germany, 3Institute of Lightweight Design and
Structural Biomechanics, Vienna University of Technology, Vienna,
Austria, 4Matrix Biochemistry, Rowett Research Institute,
Aberdeen, United Kingdom |
|
| 16:40 |
Mo-OP23 |
USE OF THIAZIDE DIURETICS AND RISK OF HIP/FEMUR FRACTURE:
A POPULATION-BASED CASE-CONTROL STUDY AND THE FIRST-EVER META-ANALYSIS
OF DOUBLE BLINDED RCTS
F. De Vries*1, B. Thio1, D. Altug1,
K. Ozer1, H. G. M. Leufkens1, C. Cooper2,
T. van Staa1
1Pharmacoepidemiology and Pharmacotherapy,
Utrecht Institute for Pharmaceutical Sciences, Utrecht, Netherlands,
2MRC Epidemiology Resource Centre, Southampton General
Hospital, University of Southampton, Southampton, United Kingdom |
|
| 16:45 |
Mo-OP24 |
EFFICACY OF BAZEDOXIFENE IN REDUCING NEW VERTEBRAL
FRACTURE RISK IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS: RESULTS FROM
A 3-YEAR, RANDOMIZED, PLACEBO- AND ACTIVE-CONTROLLED CLINICAL TRIAL
H. K. Genant*1, S. L. Silverman2, C. Christiansen3,
J. R. Zanchetta4, I. Valter5, T. J. de Villiers6,
G. Constantine7, A. A. Chines7
1,
University of California, San Francisco and Synarc, Inc., San Francisco,
CA, 2, Cedars-Sinai Medical Center and University of California,
Los Angeles, CA, United States, 3, Center for Clinical
and Basic Research, Ballerup, Denmark, 4, University of
El Salvador, Metabolic Research Institute, Buenos Aires, Argentina,
5, Center for Clinical and Basic Research, Tallinn, Estonia,
6, Panorama MediClinic and University of Stellenbosch,
Cape Town and Stellenbosch, South Africa, 7, Wyeth Pharmaceuticals,
Collegeville, PA, United States |
|
| 16:50 |
Mo-OP25 |
COMPARATIVE EFFECTS OF TERIPARATIDE AND
STRONTIUM RANELATE ON BIOCHEMICAL BONE MARKERS AND ILIAC CREST BIOPSIES
IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
R. R. Recker*1, J. Stepan2, P. de la Peña3,
R. Moericke4, F. Hawkins5, G. Kapetanos6,
S. Ish-shalom7, J. Kekow8, B. Sanz9,
H. Oertel9, F. Marin9
1Osteoporosis
Res. Ctr., Creighton Univ., Omaha, United States, 2Fac.
Medicine, Charles Univ., Prague, Czech Republic, 3Especialidades,
Clin. Med. Monraz, Guadalajara, Mexico, 4Endocrinology,
Clin. Res. Lab., Magdeburg, Germany, 5Endocrinology, H.
12 de Octubre, Madrid, Spain, 6Orthopedic Surgery, Aristotelion
Univ., Thessaloniki, Greece, 7Metabolic Bone Res. Unit,
Rambam Medical Center, Haifa, Israel, 8Rheumatology, Speciality
Hospital, Vogelsang-Gommern, Germany, 9Lilly Research Center,
Lilly, Windlesham, United Kingdom |
|
| 16:55 |
Mo-OP26 |
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED
STUDY OF ODANACATIB (MK-822) IN THE TREATMENT OF POSTMENOPAUSAL WOMEN
WITH LOW BMD: 18-MONTH RESULTS
M. McClung*1, H. Bone2, N. Verbruggen3,
A. Rybak-Feiglin4, C. daSilva4, A. Santora4,
A. Ince4
1Medicine, Oregon Osteoporosis
Center, Portland, 2Medicine, Michigan Bone and Mineral
Center, Detroit, United States, 3MRL, Merck and Co., Inc.,
Brussels, Belgium, 4MRL, Merck and Co., Inc., Rahway, United
States |
|
| 17:00 |
Mo-OP27 |
THE 10-YEAR PROBABILITY OF RECURRENT OSTEOPOROTIC
FRACTURES IN POSTMENOPAUSAL WOMEN AFTER A WRIST FRACTURE, AND THE
NUMBER NEEDED TO TREAT FOR 5 YEARS WITH AN ORAL BISPHOSHONATE TO PREVENT
A SECONDARY FRACTURE
A. B. Hodsman*1, J. F. Tsang2, W. D. Leslie3
1Department of Medicine, University of Western Ontario,
London, 2Faculty of Medicine, 3Department of
Medicine, University of Manitoba, Winnipeg, Canada |
|
| 17:05 |
Mo-OP28 |
CAN FALL RISK BE INCORPORATED INTO FRACTURE
RISK ASSESSMENT ALGORITHMS: A PILOT STUDY OF RESPONSIVENESS TO BISPHOSPHONATES.
H. Johansson*1, A. Oden1, K. Kayan1,
J. Kanis1, E. McCloskey1
1WHO
Collaborating Centre for Metabolic Bone Diseases, University of Sheffield,
Sheffield, United Kingdom |
|
| 17:10 |
Mo-OP29 |
INCREASED INTEGRAL BONE MINERAL DENSITY
(BMD) OF THE HIP WITH ONCE-YEARLY ZOLEDRONIC ACID 5 MG (ZOL): QUANTITATIVE
COMPUTED TOMOGRAPHY DATA (QCT) FROM THE HORIZON-PFT TRIAL
R. Eastell*1, T. Lang2, S. Boonen3,
S. Cummings4, P. D. Delmas5, J. Cauley6,
Z. Horowitz7, E. Kerzberg8, P. Leung9,
Z. Man10, P. Mesenbrink11, E. F. Eriksen12,
D. Black13
1Department of Human Metabolism
and Clinical Biochemistry, University of Sheffield, Sheffield, United
Kingdom, 2Department of Radiology, University of California,
San Francisco, United States, 3Leuven University Center
for Metabolic Bone Diseases and Division of Geriatric Medicine, Katholieke
Universiteit Leuven, Leuven, Belgium, 4CPMC Research Institute,
University of California, San Francisco, United States, 5INSERM
Research Unit 831 and University of Lyon, University of Lyon, Lyon,
France, 6Department of Epidemiology, University of Pittsburgh,
Pittsburgh, 7Chief Medical Officer, Savient Pharmaceuticals,
New Jersey, United States, 8Argentine Reference Center
in Osteoporosis, Hospital Ramos Mejia, Buenos Aires, Argentina, 9Faculty
of Medicine, Chinese University of Hong Kong, Hong Kong, China, 10Centro
TIEMPO, Universidad Favaloro, Buenos Aires, Argentina, 11Department
of Biostatistics, Novartis Pharmaceuticals Corporation, New Jersey,
United States, 12Clinical Research and Development, Novartis
Pharma AG, Basel, Switzerland, 13Department of Epidemiology
and Biostatistics, University of California, San Francisco, United
States |
|
| 17:15 |
Mo-OP30 |
INCREASED INCIDENCE OF ATRIAL FIBRILLATION
AND ISCHAEMIC STROKE IN FRACTURE PATIENTS TREATED WITH ORAL BISPHOSPHONATES
- A NATIONAL REGISTER STUDY
B. Abrahamsen*1, P. Eiken2, K. Brixen3
1Dept of Medicine F, Copenhagen University Hospital Gentofte,
Hellerup, 2Dept of Medicine, Nordsjællands Hospital,
Hillerød, 3Dept of Endocrinology, Odense University
Hospital, Odense, Denmark |
|
| 17:20 |
Mo-OP41 |
EFFICACY OF ADDING TERIPARATIDE VERSUS
SWITCHING TO TERIPARATIDE IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
PREVIOUSLY TREATED WITH RALOXIFENE OR ALENDRONATE
F. Cosman*1, R. A. Wermers2, C. Recknor3,
K. F. Mauck4, L. Xie5, E. V. Glass5,
J. H. Krege5
1Clinical Research Center,
Helen Hayes Hospital, West Haverstraw, 2Endocrinology,
Mayo Clinic, Rochester, 3Clinical Research, United Osteoporosis
Centers, Gainesville, 4General Internal Medicine, Mayo
Clinic, Rochester, 5Lilly Research Labs, Eli Lilly and
Company, Indianapolis, United States |
|
16:30-
17:30 |
|
Short
Oral Communications 4: Basic
Chairs: Arantxa de Gortázar (Madrid, Spain)
Marie Christine De Vernejoul (Paris, France) |
|
| 16:30 |
Mo-OP31 |
MICE LACKING NEURONAL NOS SHOW ACCELERATED BONE LOSS
AFTER OVARIECTOMY
A. Thomas*1, L. Rose1, S. H. Ralston1,
R. J. van 't Hof1
1Rheumatology, University
of Edinburgh, Edinburgh, United Kingdom |
|
| 16:35 |
Mo-OP32 |
PROGRESSIVE ANKYLOSIS GENE (ANK) REGULATES OSTEOBLAST
DIFFERENTIATION
T. Kirsch*1, H. Kim1, J. A. Winkles2
1Orthopaedics, 2Surgery, University of Maryland
School of Medicine, Baltimore, United States |
|
| 16:40 |
Mo-OP33 |
HETEROGENEITY BETWEEN CALVARIAL AND LONG BONE OSTEOCLASTS
WITH RESPECT TO THE INTERNAL PH REGULATION
I. D. Jansen*1, T. J. de Vries1, M. M. van Borren2,
J. Ravesloot2, R. P. Oude Elferink3, V. Everts4
1Periodontology and Oral Cell Biology, ACTA, 2Dept.
of Physiology, 3AMC Liver Center, AMC, 4Oral
Cell Biology, ACTA, Amsterdam, Netherlands |
|
| 16:45 |
Mo-OP34 |
BIDIRECTIONAL REGULATION OF PEAK BONE MASS AND AGE-RELATED
BONE LOSS BY THE TYPE 1 CANNABINOID RECEPTOR
A. I. Idris*1, A. Sophocleous1, E. Landao-Bassonga1,
R. van’t Hof1, S. H. Ralston1
1Rheumatology,
University of Edinburgh, Edinburgh, United Kingdom |
|
| 16:50 |
Mo-OP35 |
IDENTIFICATION OF A NOVEL LOSS-OF-FUNCTION
MISSENSE MUTATION IN THE RANKL GENE THAT CAUSES OSTEOPETROSIS IN MICE
E. Douni*1, E. Makrinou1, G. Kollias1
1Institute of Immunology, B.S.R.C. Alexander Fleming, Vari,
Greece |
|
| 16:55 |
Mo-OP36 |
THE EFFECTS AND MECHANISM OF PROLACTIN
ON OSTEOBLAST DIFFERENTIATION
D. Seriwatanachai*1, N. Krishnamra2, M. Koedam1,
J. P. T. M. van Leeuwen1
1Internal Medicine,
Erasmus MC, Rotterdam, Netherlands, 2Physiology, Mahidol
University, Bangkok, Thailand |
|
| 17:00 |
Mo-OP37 |
THE NOVEL VITAMIN D ANALOG ZK191784 NORMALIZES
THE DECREASED BONE MATRIX MINERALIZATION IN MICE LACKING THE EPITHELIAL
CALCIUM CHANNEL TRPV5: A QBEI STUDY
N. Fratzl-Zelman*1, B. C. J. van der Eerden2,
P. Roschger1, T. Nijenhuis3, J. G. J. Hoenderop3,
U. Zügel4, B. Misof1, R. Bindels3,
K. Klaushofer1, J. P. T. M. van Leeuwen2
1Ludwig Boltzmann Institute of Osteology, Hanusch Hospital
of WGKK and AUVA Trauma Centre Meidling, 4th Med. Dept., Hanusch Hospital,
Vienna, Austria, 2Internal Medicine, Erasmus MC, Rotterdam,
3Cell Physiology, Nijmegen Center for Molecular Life Sciences,
Radboud University MC, Nijmegen, Netherlands, 4Schering
AG, Berlin, Germany |
|
| 17:05 |
Mo-OP38 |
REGULATION OF KLOTHO EXPRESSION BY ESTROGEN
O. K. Oz*1, A. Hajibeigi1, M. Kuro-o2
1Radiology, 2Pathology, UT Southwestern Medical
Center at Dallas, Dallas, United States |
|
| 17:10 |
Mo-OP39 |
IDENTIFICATION OF NOVEL UNSUSPECTED MOLECULAR
TARGETS OF NITROGEN-CONTAINING BISPHOSPHONATES THROUGH BARCODE TECHNOLOGY
N. Bivi*1, M. Romanello1, R. Harrison2,
F. Quadrifoglio1, D. Delneri2, L. Moro3,
G. Tell1
1Department of Biomedical Sciences
and Biotechnology, University of Udine, Udine, Italy, 2Faculty
of Life Sciences, University of Manchester, Manchester, United Kingdom,
3The Center for the Study of Metabolic Bone Diseases, The
Center for the Study of Metabolic Bone Diseases, Gorizia, Italy |
|
| 17:15 |
Mo-OP40 |
VISUALISATION OF CELLULAR UPTAKE AND LOCALISATION
OF BISPHOSPHONATE IN VIVO USING A FLUORESCENT ANALOGUE OF RISEDRONATE
A. J. Roelofs*1, F. P. Coxon1, F. H. Ebetino2,
J. F. Bala3, B. A. Kashemirov3, C. E. McKenna3,
M. J. Rogers1
1Department of Medicine and
Therapeutics, University of Aberdeen, Aberdeen, United Kingdom, 2New
Drug Development, Procter and Gamble Pharmaceuticals, Cincinnati,
3Department of Chemistry, University of Southern California,
Los Angeles, United States |
|
|
|
|
